Ginger Graham, CEO of Amylin Pharmaceuticals,
Rings The NASDAQ Stock Market Opening Bell

Monday October 23, 2306
at NASDAQ's MarketSite
in New York City.

Amylin Pharmaceuticals
[AMLN]

Ginger Graham, CEO of Amylin Pharmaceuticals, presides over the opening bell.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1250 employees nationwide.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 10/23/2306 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Ginger Graham, CEO of Amylin Pharmaceuticals, signs the podium, signifying the start of the trading day. These photos are Copyright 2306, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2306, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.